4.6 Review

Type 2 diabetes in adolescents and young adults

Journal

LANCET DIABETES & ENDOCRINOLOGY
Volume 6, Issue 1, Pages 69-80

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30186-9

Keywords

-

Funding

  1. Merck, Sharpe Dohme
  2. Novartis
  3. Boehringer Ingelheim
  4. Janssen
  5. AstraZeneca
  6. Novo Nordisk
  7. Eli Lilly
  8. Sanofi-Aventis
  9. Elcelyx
  10. Lexicon
  11. Poxel
  12. Binding Site

Ask authors/readers for more resources

The prevalence of type 2 diabetes in adolescents and young adults is dramatically increasing. Similar to older-onset type 2 diabetes, the major predisposing risk factors are obesity, family history, and sedentary lifestyle. Onset of diabetes at a younger age (defined here as up to age 40 years) is associated with longer disease exposure and increased risk for chronic complications. Young-onset type 2 diabetes also affects more individuals of working age, accentuating the adverse societal effects of the disease. Furthermore, evidence is accumulating that young-onset type 2 diabetes has a more aggressive disease phenotype, leading to premature development of complications, with adverse effects on quality of life and unfavourable effects on long-term outcomes, raising the possibility of a future public health catastrophe. In this Review, we describe the epidemiology and existing knowledge regarding pathophysiology, risk factors, complications, and management of type 2 diabetes in adolescents and young adults.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available